Anti-liver fibrosis effect of pegylated interferon α2b combined with Ganfule capsules on patients with HbeAg postive CHB,China
ZHANG Jiwan1, ZHOU Jianli2, ZHANG Xiaofang3, LONG Li3, and WU Gang4
1.Division of Medical Affairs,2.Administrative Office, 3.Department of Infectious Diseases,Sichuan Provincial Corps Hospital of Chinese People’s Armed Police Force,Leshan 614000,China; 4.Department of Infectious Diseases, the Affiliated Hospital of Southwest Medical University, luzhou 646000,China
Abstract：Objective To investigate the anti-liver fibrosis effect of pegylated interferon α2a(Peg-IFN-α2a) combined with Ganfule capsules on patients with HbeAg postive chronic hepatitis B(CHB).Methods 108 patients with HbeAg postive CHB were divided into two groups. Patients in group A(n=56) were treated with Peg-IFN-α2a and Ganfule capsules, while patients in group B(n=52) were treated with Peg-IFN-α2a alone. The course of treatment of the two groups was 48 weeks. The liver function, HBV DNA level, serum marker of liver fibrosis and Fibroscan score over the 48 weeks were collected and analyzed. ELISA method was performed to measure the level of serum hyaluronic acid (HA), laminin (LN), procollagen Ⅲ N-terminal peptide (PⅢP), and type Ⅳ collagen (CⅣ).Results At the 48 th week, the level of HBV DNA (LOG10 copies/ml) was decreased from (6.78±1.36 )to (2.36±0.42 ) in group A and from( 6.54±1.25 )to( 2.43±0.37)in group B. The level of ALT was decreased from(106.62±36.74)U/L to (33.22±8.75)U/L group A and that from(113.57±40.29)U/L to(40.64±11.37)U/L group B. The level of HBV DNA and ALT in both groups was significantly decreased compared with the level at baseline (P<0.01). The level of serum HA, LN, PⅢP and CⅣ in both groups was also significantly decreased (P<0.01). Furthermore, the levels of serum HA, LN, PⅢP and CⅣ at the 48 th week were significantly lower in group A (P<0.05). The Fibroscan score of group A were decreased from(12.78±3.32)Kpa to(7.43±2.21)Kpa and that of group B from (13.34±3.35)kPa to(9.24±2.06)kPa. The Fibroscan scores in both groups were significantly decreased compared with the level at baseline (P<0.01).Also, Fibroscan scores at the 48th week were significant lower in group A than in group B(P<0.05).Conclusions The combination of Peg-IFN-α2a with Ganfule capsules can more effectively improve liver fibrosis of patients with HbeAg postive CHB.
Lok A S, Mc Mahon B J, Brown R S, et al. Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis[J]. Hepatology, 2016,63(1):284-306.
[2]
Shin S K, Kim J H, Park H, et al. Improvement of liver function and non-invasive fibrosis markers in hepatitis B virus-associated cirrhosis: 2 years of entecavir treatment[J]. J Gastroenterol Hepatol, 2015,30(12):1775-1781.
2017, Vol. 28 
